Endo combined with Mallinckrodt Pharmaceuticals in 2025 to better serve customers and improve outcomes for the patients we support.From this union, we established two focused, standalone companies:– Keenova Therapeutics, a branded therapeutics business– Par Health, a generics and sterile injectables businessTo learn more, follow Keenova and Par Health on LinkedIn and visit keenova.com and parhealth.com.